Breast cancer in systemic lupus erythematosus (SLE) : receptor status and treatment
(2018) In Lupus 27(1). p.120-123- Abstract
Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2... (More)
Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).
(Less)
- author
- organization
- publishing date
- 2018-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Breast cancer, estrogen, progesterone, receptor, systemic lupus erythematosus
- in
- Lupus
- volume
- 27
- issue
- 1
- pages
- 4 pages
- publisher
- SAGE Publications
- external identifiers
-
- scopus:85038447514
- pmid:28595511
- ISSN
- 0961-2033
- DOI
- 10.1177/0961203317713146
- language
- English
- LU publication?
- yes
- id
- 76168e42-4199-4a9a-b123-f8ccc658e41a
- date added to LUP
- 2018-01-02 15:03:05
- date last changed
- 2024-09-17 12:35:38
@article{76168e42-4199-4a9a-b123-f8ccc658e41a, abstract = {{<p>Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).</p>}}, author = {{Chan, K. and Clarke, A. E. and Ramsey-Goldman, R. and Foulkes, W. and Tessier Cloutier, B. and Urowitz, M. B. and Gladman, D. and Nived, O. and Romero-Diaz, J. and Petri, M. and Ginzler, E. and Fortin, P. R. and Bae, S. C. and Wallace, D. J. and Yelin, E. H. and Bernatsky, Sasha}}, issn = {{0961-2033}}, keywords = {{Breast cancer; estrogen; progesterone; receptor; systemic lupus erythematosus}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{120--123}}, publisher = {{SAGE Publications}}, series = {{Lupus}}, title = {{Breast cancer in systemic lupus erythematosus (SLE) : receptor status and treatment}}, url = {{http://dx.doi.org/10.1177/0961203317713146}}, doi = {{10.1177/0961203317713146}}, volume = {{27}}, year = {{2018}}, }